Rare Diseases: Considerations for the Development of Drugs and Biological Products (From Catapult’s regulatory round-up – January 2024)
The FDA has issued a final guidance for industry entitled “Rare Diseases: Considerations for the Development of Drugs and Biological Products.” This guidance is intended to assist sponsors of drugs and biological products for treatment of rare diseases in conducting efficient and successful drug development programs through a discussion of selected issues commonly occurring in rare disease drug development.
News Published on the 6th of february 2024. Read the entire regulatory round-up for January following this link.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (9 août 2024). Rare Diseases: Considerations for the Development of Drugs and Biological Products (From Catapult’s regulatory round-up – January 2024). ELSIBI. Consulté le 18 mars 2025 à l’adresse https://doi.org/10.58079/125n3